Clinical Trial Results: A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) [Phase 2]

View source ↗

Summary

Phase 2 study results for efruxifermin in patients with compensated cirrhosis due to NASH have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• efruxifermin (efruxifermin)

Snippet

Sponsor: Akero Therapeutics, Inc | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2026-07-21